Deals
Sanofi to Buy Amunix for Up to $1.2 Billion for Cancer Drugs
Logos on the Sanofi exhibition stand at the Viva Technology conference.
Photographer: Nathan Laine/BloombergThis article is for subscribers only.
Sanofi agreed to buy privately held Amunix Pharmaceuticals Inc. for as much as $1.2 billion to increase its pipeline of promising cancer medicines.
The French drugmaker will pay $1 billion upfront and up to $225 million if future development milestones are reached, the companies said in a statement Tuesday.